ATR12-351

Phase 1Small molecule

AAzitra Inc.

ATR12-351 is one of 7 small molecule programs targeting Netherton syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Netherton SyndromeActive, not recruiting

Netherton SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Netherton Syndrome

#DrugCompanyPhaseTrials

Elidel

BBausch Health Americas, Inc.

Spevigo

1 3

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 4

Humira

CCelltrion

Phase 2

1 5

Ds-2325a

Daiichi Sankyo

Phase 2

1 6

Stool Collect

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 7

ATR12-351

AAzitra Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Netherton Syndrome

NCT06137157

Clinical

Trials by Indication[1]

Netherton syndrome1 trial

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Recruiting·AAzitra Inc.·Phase 1·NCT06137157·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATR12-351. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATR12-351 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATR12-351. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azitra Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAzitra Inc.

ATR12-351

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Netherton syndrome1 trial

References

Drug Info

Quick Facts

Related News